6-K: Supernova Phase Iii Trial of Sipavibart Long-Acting Antibody Met Primary Endpoints in Preventing Covid-19 in Immunocompromised Patient Population
6-K: Supernova Phase Iii Trial of Sipavibart Long-Acting Antibody Met Primary Endpoints in Preventing Covid-19 in Immunocompromised Patient Population
阿斯利康 | 6-K：Sipavibart長效抗體超新星III期試驗在免疫功能低下患者群體中預防Covid-19方面達到主要目標
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。